Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis

OBJECTIVES: To assess the efficacy and safety of abatacept, a selective T-cell costimulation modulator, in a phase III study in psoriatic arthritis (PsA). METHODS: This study randomised patients (1:1) with active PsA (~60% with prior exposure to a tumour necrosis factor inhibitor) to blinded weekly...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Gottlieb, Alice B, van der Heijde, Désirée, FitzGerald, Oliver, Johnsen, Alyssa, Nys, Marleen, Banerjee, Subhashis, Gladman, Dafna D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Annals of the Rheumatic Diseases 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561378/
https://www.ncbi.nlm.nih.gov/pubmed/28473423
http://dx.doi.org/10.1136/annrheumdis-2016-210724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561378/
https://www.ncbi.nlm.nih.gov/pubmed/28473423
http://dx.doi.org/10.1136/annrheumdis-2016-210724

Ejemplares similares